US · Healthcare · Medical Devices
EPS came in at 0.56 against a street estimate of 0.42 — a beat of 33.3%.
Analysts rate Bruker Corporation a buy (6 buy, 6 hold, 1 sell out of 13) with an average price target of $63.83.
CONFIDENT Bruker returned to organic growth in Q2 (2.8%) with strong margin expansion (+350 bps gross, +510 bps operating) driven by cost cuts ($30M in Q2). Deep tech (semiconductors, security, fusion) bookings soared 50%+ but face 6-24 month delays. Q4 expected to deliver $1B+ revenue with significant EPS lift. Q2 FY26 Geopolitical headwinds and tariffs pressured Asia. Europe led growth; U.S. academic funding weak but orders improving outside U.S. Analysts pressed on tariff treatment and revenue recognition timing; management clarified tariff refunds flowed through to margin (+200 bps) and deep tech orders have inherent delays. Weak U.S. academic funding highlighted as main near-term headwind; semicon and fusion demand called sustainable but customer-paced. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 13.28% |
| Orbis Allan Gray Ltd | 11.77% |
| BlackRock Inc | 7.49% |
| Pallas Capital Advisors LLC | 6.22% |
| Vanguard Portfolio Management, LLC | 3.21% |
| Vanguard Capital Management, LLC | 3.19% |
| OZ Management LLC | 3.04% |
| State Street Corp | 2.64% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $874.0 million, up from $860.5 million in the third quarter of 2025. • Nine-month 2026 revenue was | 2026-11-05 |
| Company announcement · Q4 2026 BUSINESS & SEGMENT HIGHLIGHTS • Effective July 1, 2026, Bruker reorganized its four reportable segments to streamline decision-making, accountability | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3-26 revenue was $874.0 million, up 1.6% year over year and up 0.7% organically. • Q3-26 non-GAAP operating margin was 16.3%, co | 2026-11-04 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Bruker Corporation declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Se | 2026-10-29 |
| Company announcement · Q3 2026 BRUKER CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • Quarterly cash dividend declared: $0.05 per share • Dividend declaration date: August 14, 2026 • | 2026-08-14 |
| Quarterly report · Q2 2026 BRUKER CORPORATION - 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Revenue (6 months): $1,661.9 million vs. $1,598.8 mi | 2026-08-05 |
| Results announced · Q3 2026 BRUKER CORPORATION Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2-26 revenue $838.5 million, up 5.2% year-over-year; organic growth 2.8% (or 3.4% ex | 2026-08-04 |
| Company announcement · Q3 2026 BRUKER CORPORATION (BRKR) - 8-K SUMMARY HEADLINE NUMBERS • Quarterly cash dividend declared on 6.375% Mandatory Convertible Preferred Stock, Series | 2026-07-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.05 / share ex-date Sep 21, 2026 · pay Oct 7, 2026 | 2026-09-21 |
| Dividend | $0.05 / share ex-date Jun 22, 2026 · pay Jul 7, 2026 | 2026-06-22 |
| Dividend | $0.05 / share ex-date Mar 23, 2026 · pay Apr 7, 2026 | 2026-03-23 |
| Dividend | $0.05 / share ex-date Dec 8, 2025 · pay Jan 2, 2026 | 2025-12-08 |
| Announcement | Date |
|---|---|
| FY2026 organic revenue growth and non-GAAP EPS guidance reaffirmed Bruker reported a mixed but generally improving third quarter. Revenue rose 1.6% year over year to $874.0 million, including 0.7% organic growth. The BEST segment grew strongly, while Bruker | 2026-11-04 |
| FY2026 guidance updated for currency and tax impacts Bruker Corporation reported Q2 2026 results with mixed but improving signals. Revenue reached $838.5 million, up 5.2% year-over-year, though organic growth was modest at 2.8%. The key bright | 2026-08-04 |
| Q1 2026 results reported; FY2026 guidance reconfirmed with organic growth expectations Bruker Corporation reported Q1 2026 revenues of $823.4 million, up 2.7% year-over-year, but organic revenue declined 4.4%—a concerning sign masked by favorable foreign currency effects and a | 2026-05-06 |
| FY26 revenue and EPS guidance initiated; expects 4-5% revenue growth Bruker Corporation reported challenging 2025 results but provided optimistic 2026 guidance. In Q4 2025, revenues were $977.2 million (flat year-over-year but down 5% organically), with non-G | 2026-02-12 |
| Q4 2025 revenue guidance and 2026 outlook provided at healthcare conference Bruker Corporation announced preliminary Q4 2025 revenue guidance of $965-970 million during a January 12, 2026 healthcare conference presentation. The company's Scientific Instruments segme | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bruker Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.